Skip to main content
SpringerLink
Log in

Metabolism of propranolol in the human maternal-placental-foetal unit

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Propranolol (P) and all of its major known metabolites were found in maternal plasma, cord plasma and neonatal plasma in 10 women at term, irrespective of the P doses administered and the time elapsed (up to 15 h) between administration of the last P dose and delivery. The ratios of cord plasma to simultaneous maternal plasma levels for propranolol and its major metabolites (mean±SD) were: propranolol 0.32±0.17, propranolol glucuronide 0.86±0.36, 4-hydroxypropranolol 1.4±1.0, 4-hydroxypropranolol glucuronide 0.71±0.45 and naphthoxylactic acid 3.0±1.6. P binding in cord plasma at delivery was 67.2±3.9% (mean±SD) which was significantly less (‘t’=13.4,df=13,p<0.001) than the P binding in maternal plasma at delivery (87.5±1.6%, mean±SD). The plasma protein binding (mean±SD) of naphthoxylactic acid in cord plasma (98.6±0.2%) was significantly greater (‘t’=3.808,df=4,p<0.02) than the naphthoxylactic acid binding in maternal plasma at delivery (97.6±0.4%). When the simultaneous concentrations of P and naphthoxylactic acid in maternal and cord plasma are compared in conjunction with protein binding and ionic effects, it would seem that metabolism of P does occur in the placental/foetal unit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Cottrill CM, McCallister RG Jr, Gettes L, Noonan JA (1977) Propranolol therapy during pregnancy, labour, and delivery. Evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr 91: 812–814

    Google Scholar 

  • Goldstein A, Aronow L, Kolman SM (1974) In: Principles of drug action: The basis of pharmacology. Wiley, New York, p 201

    Google Scholar 

  • Hitzig WH (1963) Die Plasmaproteine in der klinischen Medizin. Springer, Berlin. In: Diem K, Lentner C (eds) Documenta Geigy, Scientific tables (1970). Ciba-Geigy Ltd. (publishers), Basle, Switzerland, p 583

    Google Scholar 

  • Juchau MR (1976a) Drug biotransformation reactions in the placenta. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 112

    Google Scholar 

  • Juchau MR (1976b) Drug biotransformation reactions in the placenta. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 114

    Google Scholar 

  • Juchau MR, Chao ST, Omiecinski CJ (1980) Drug metabolism in the human foetus. Clin Pharmacokinet 5: 320–339

    Google Scholar 

  • Kosman ME (1973) Current status of propranolol hydrochloride (Inderal). Am J Med Assoc 225: 1380

    Google Scholar 

  • Levitan AA, Manion JC (1973) Propranolol therapy during pregnancy and lactation. Am J Cardiol 32: 247

    Google Scholar 

  • Mirkin BL, Singh S (1976) Placental transfer. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 26

    Google Scholar 

  • Pelkonen O (1980) Environmental influences on human foetal and placental xenobiotic metabolism. Eur J Clin Pharmacol 18: 17–24

    Google Scholar 

  • Rankin J, Meschia G, Makowski EL, Battaglia FF (1970) Placental transfer. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 17

    Google Scholar 

  • Smith MT, Livingstone I, Hooper WD, Eadie MJ, Triggs EJ (1983) Propranolol, propranolol glucuronide and naphthoxylactic acid in breast milk and plasma. Ther Drug Monitoring (in press)

  • Waddell WJ, Marlowe GC (1976) Disposition of drugs in the foetus. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 221

    Google Scholar 

  • Walle T, Gaffney TE (1972) Propranolol metabolism in man and dog: Mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther 182: 83–92

    Google Scholar 

  • Wood M, Wood AJJ (1981) Changes in plasma drug binding and α1-acidglycoprotein in mother and newborn infant. Clin Pharmacol Ther 29: 522–526

    Google Scholar 

  • Yaffe MR, Stern L (1976) Clinical implications of perinatal pharmacology. In: Mirkin BL (ed) Perinatal pharmacology and therapeutics. Academic Press, New York, p 382

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia

    M. T. Smith, M. J. Eadie & W. D. Hooper

  2. Royal Womens Hospital, University of Queensland, Brisbane, Australia

    I. Livingstone

  3. Department of Pharmacy, University of Queensland, Brisbane, Australia

    E. J. Triggs

Authors
  1. M. T. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Livingstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. J. Eadie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. D. Hooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. J. Triggs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, M.T., Livingstone, I., Eadie, M.J. et al. Metabolism of propranolol in the human maternal-placental-foetal unit. Eur J Clin Pharmacol 24, 727–732 (1983). https://doi.org/10.1007/BF00607078

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00607078

Key words

Search

Navigation